Radioimmunoassay for γ-endorphin

A double antibody radioimmunoassay technique for γ-endorphin has been developed. The antisera have been raised in rabbits against synthetic γ-endorphin coupled to bovine serum albumin by carbodiimide. The best antibody has a working titer of $\text{1}\text{35,000}$ and can detect less than 9 pg of peptide. The usable range of the standard curve is between 9 to 2400 pg. This antiserum probably binds the Glu⁸-Leu¹⁷ region of γ-endorphin and shows only weak cross-reactivity with α-endorphin, β-endorphin and β-lipotropin. Parallelism is observed between the standard curve and the inhibition curves obtained with rat neurohypophysis-pars intermedia extracts or rat plasma.     

Nonopioid effect of β-endorphin

This review presents the generalized literature data and the results of our own research of the nonopioid effect of β-endorphin, an opioid neuropeptide interacting not only with opioid but also with nonopioid (insensitive to the opioid antagonist naloxone) receptors. The roles of the hormone and its receptors in regulation of the immune, nervous, and endocrine systems are discussed. The effect of neuromediator on the immune system mediated by both opioid and nonopioid receptors is considered in detail. The data on distribution and function of the nonopioid β-endorphin receptor in human and animal organisms are presented. All available data on the characteristics of the nonopioid β-endorphin receptor obtained by means of radioligand analysis are given. The discussed information is supposed to extend our conceptions of the role of β-endorphin in mammals and to be of extensive use in medicine and pharmacology.     

Solid phase synthesis of porcine α-endorphin and γ-endorphin,two hypothalamic-pituitary peptides with opiate activity

The synthesis by solid phase methodology of α-endorphin (Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-OH) and γ-endorphin (Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-OH), two morphinomimetic peptides isolated from pig hypothalamus-pituitary extracts, is described. The sequences of these two peptides correspond to residues 61–76 and 61–77, respectively, of porcine β-lipotropin. The two synthetic compounds were shown to have the same physical, chemical and opiate activity as the respective native substances.     

Interaction of α-N-acetyl-β-endorphin and calmodulin

Acetylation at the α-amino terminal is a common post-translational modification of many peptides and proteins. In the case of the potent opiate peptide β-endorphin, α-N-acetylation is a known physiological modification that abolishes opiate activity. Since there are no known receptors for α-N-acetyl-β-endorphin, we have studied the association of this peptide with calmodulin, a calcium-dependent protein that binds a variety of peptides, phenothiazines, and enzymes, as a model system for studying acetylated endorphin-protein interactions. Association of the acetylated peptide with calmodulin was demonstrated by cross-linking with bis(sulfosuccinimidyl)suberate; like β-endorphin, adducts containing 1 mol and 2 mol of acetylated peptide per mole calmodulin were formed. Some of the bound peptides are evidently in relatively close proximity to each other since, in the presence of amidated (i.e., lysine-blocked) calmodulin, cross-linking yielded peptide dimers. The acetylated peptide exhibited no appreciable helicity in aqueous solution, but in trifluoroethanol (TFE) considerable helicity was formed. Also, a mixture of acetylated peptide and calmodulin was characterized by a circular dichroic spectrum indicative of induced helicity. Empirical prediction rules, applied earlier to β-endorphin, suggest that residues 14–24 exhibit α-helix potential. This segment has the potential of forming an amphipathic helix; this structural unit is believed to be important in calmodulin binding. The acetylated peptide was capable of inhibiting the calmodulin-mediated stimulation of cyclic nucleotide phosphodiesterase (EC 3.1.4.17) activity with an effective dose for 50% inhibition of about 3 µM; this inhibitory effect was demonstrated using both an enzyme-enriched preparation as well as highly purified enzyme. Thus, acetylation at the α-amino terminal of β-endorphin, although abolishing opiate activity, does not interfere with the binding to calmodulin. Indeed, β-endorphin and the α-N-acetylated peptide behave very similarly with respect to calmodulin association.     

Effects of β-endorphin on brain serotonin metabolism

Human β-endorphin (15 μg) administered intracisternally increased concentrations of serotonin (5HT) and its metabolite, 5-hydroxyindoleacetic. acid (5-HIAA), in brain stem and hypothalamus and decreased 5-HIAA concentrations in hippocampus. These data are compatible with the hypothesis that β-endorphin increases 5HT turnover in brain stem and hypothalamus and decreases 5HT turnover in hippocampus. β-endorphin increased in brain stem and hypothalamus and decreased in hippocampus the rate of pargyline-induced decline of 5-HIAA. β-endorphin decreased the rate of pargyline-induced accumulation of 5HT in all these brain regions. The probenecid-induced accumulation of 5-HIAA in brain stem was decreased by β-endorphin. These data are compatible with the hypothesis that β-endorphin increases release of 5HT from neurons in brain stem and hypothalamus and decreases release of 5HT from neurons in hippocampus. The data require further a hypothesis that β-endorphin either decreases 5HT reuptake in these three brain regions or increases 5-HIAA egress from brain.     

Cross tolerance between morphine and β-endorphin in vivo

Experiments were performed to establish the development of cross tolerance between morphine and the C-terminal fragment of porcine β-lipotropin /LPH_61–91, β-endorphin/ in rats. Repeated intracerebroventricular /ICV/ or peripheral administration of morphine induced tolerance both to morphine and β-endorphin. The tolerance induced by ICV administration of morphine was more pronounced than in the case of peripheral application. The results give support to the theory that at least in part similar sites and mechanisms are involved in the analgesic activity of morphine and the endorphins.     

β-endorphin: Dose-dependent suppression of fixed-ratio operant behavior

Centrally administered β-endorphin or morphine suppressed fixed-ratio 15, food-reinforced responding by rats in a dose- dependent manner. β-Endorphin was 21 times more potent than morphine on a molar basis. Scratching and wet-dog shakes were observed within 30 minutes of β-endorphin administration but were not seen after morphine and did not appear to be responsible for the suppression of the conditioned behavior.     

Intracerebral des-tyrosine-γ-endorphin inhibits methylphenidate induced locomotor activity

Des-tyrosine-γ-endorphin (DTγE) administered directly into the nucleus accumbens inhibited the locomotor activity that follows the intraaccumbens injection of methylphenidate. In contrast, when DTγE was injected into the nucleus accumbens it had no effect on the locomotor behavior elicited by the direct injection of dopamine into the nucleus accumbens. These results suggest an interaction of DTγE with presynaptic rather than postsynaptic dopaminergic systems.     

β-endorphin modulates a mechanoreceptor channel in the protozoan Stentor

A series of opiate compounds was tested for their ability to depress the probability that the protozoan Stentor coeruleus would contract in response to mechanical stimulation. Of these -endorphin proved to be the most effective. The depressive effect of -endorphin is concentration-dependent with an approximate E.C.₅₀ of 3.0 M and time-dependent with the maximum depression occurring 15 min after drug exposure. The effect of -endorphin is blocked by the opiate antagonist naloxone and pertussis toxin suggesting that it is mediated by a G-protein coupled opiate receptor. -endorphin does not alter responding to photic or electrical stimuli indicating its action is specific to the mechanical stimulus transduction mechanism. In agreement with this conclusion, electrophysiological studies reveal that -endorphin decreases the amplitude of the mechanoreceptor potential without altering other membrane properties. Voltage clamp analysis shows that -endorphin acts by decreasing inward currents through the mechanoreceptor channel at transmembrane potentials between -70 and + 20 mV without affecting the outward currents observed at more depolarized voltages. The fact that a mammalian neuromodulatory peptide is capable of producing a specific modulation of an ion channel in a unicellular eukaryote indicates that mechanisms of signal transduction and neuromodulation originated at an early stage in evolution.Abbreviation DAGO [D-Ala², N-Me-Phe⁴, Gly⁵-ol]-enkephalin     

Dietary fat ingestion activates β-endorphin neurons in the hypothalamus

The opioid system regulates food choice, consumption, and reinforcement processes, especially for palatable meals such as fatty food. β-Endorphin is known as an endogenous opioid peptide produced in neurons of the hypothalamus. In this study, we found that Intralipid (fat emulsion) ingestion increased c-fos expression in β-endorphin neurons. However, intragastric infusion of Intralipid only slightly increased c-fos expression 2h after infusion. Further, dissection of glossopharyngeal nerve, innervating posterior tongue taste buds, partially but significantly decreased the Intralipid-induced c-fos expression. These results indicate that mainly the orosensory stimulation from fat may activate β-endorphin neurons, thereby promoting β-endorphin release.     

Peripheral non-viral MIDGE vector-driven delivery of β-endorphin in inflammatory pain

Background

TRPA1 has been implicated in both chemo- and mechanosensation. Recent work demonstrates that inhibiting TRPA1 function reduces mechanical hypersensitivity produced by inflammation. Furthermore, a broad range of chemical irritants require functional TRPA1 to exert their effects. In this study we use the ex-vivo skin-nerve preparation to directly determine the contribution of TRPA1 to mechanical- and chemical-evoked responses at the level of the primary afferent terminal.

Results

Acute application of HC-030031, a selective TRPA1 antagonist, inhibited all formalin responses in rat C fibers but had no effect on TRPV1 function, assessed by capsaicin responsiveness. Genetic ablation experiments corroborated the pharmacological findings as C fibers from wild type mice responded to both formalin and capsaicin, but fibers from their TRPA1-deficient littermates responded only to capsaicin. HC-030031 markedly reduced the mechanically-evoked action potential firing in rat and wild type mouse C fibers, particularly at high-intensity forces, but had no effect on the mechanical responsiveness of Aδ fiber nociceptors. Furthermore, HC-030031 had no effect on mechanically-evoked firing in C fibers from TRPA1-deficient mice, indicating that HC-030031 inhibits mechanically-evoked firing via a TRPA1-dependent mechanism.

Conclusion

Our data show that acute pharmacological blockade of TRPA1 at the cutaneous receptive field inhibits formalin-evoked activation and markedly reduces mechanically-evoked action potential firing in C fibers. Thus, functional TRPA1 at sensory afferent terminals in skin is required for their responsiveness to both noxious chemical and mechanical stimuli.     

Comparison of the behavioral effects of β-endorphin and enkephalin analogs

The behavioral effects of β-endorphin, enkephalin analogs, morphine and etorphine were briefly compared. In the tail-flick test in mice and in the wet shake test in rats, β-endorphin and D-Ala²-D-Leu⁵-enkephalin had equal antinociceptive activity; D-Ala² -Met-enkephalinamide and D-Leu⁵-enkephalin were less active. The order of activity of the enkephalin analogs and opiate alkaloids for stimulating locomotor activity in mice paralleled their analgesic activities; β-endorphin, however, had only minimal stimulatory actions. Morphine sulfate, 50 μg injected into the periaqueductal gray, produced hyperactivity but this effect was not observed with etorphine or opioid peptides. By contrast, “wet dog” shakes was observed with the opioid peptides but not with either opiate alkaloid. These heterogenous behavioral responses, which were all antagonized by naloxone, indicate that multiple types of receptors mediate the effects of opiates in the central nervous system.     

Radioimmunoassay for β-endorphin: Presence of immunoreactive “big-big” β-endorphin (“big” β-lipotropin) in human and rat pituitaries

A sensitive and specific radioimmunoassay for β-endorphin has been developed with an antiserum obtained in a rabbit immunized with β-endorphin contained in crude porcineACTH preparations. The minimal detectable quantity was 5 pg. The antiserum used reacted slightly with ovine β-lipotropin (5.5 %), but showed negligible cross-reactivity with other fragments of β-lipotropin, α-MSH and ACTH. Using this radioimmunoassay we have observed the presence of “big-big” β-endorphin (“big” β-lipotropin) with apparent molecular weights of 37,000 and 31,000 in human and rat pituitaries respectively, in addition to β-lipotropin and β-endorphin, by Sephadex gel-chromatography and sodium dodecyl sulfate polyacrylamide gel electrophoresis.     

Human β-endorphin: Development of tolerance and behavioral activity in rats

Human β-endorphin produced a potent antinociceptive response as estimated by the tail-flick test in rats after intraventricular injection. On a molar basis, the peptide was 21 times more potent than morphine and in addition, the peptide produced morphine-like catatonia and hypothermia. These responses were blocked by naloxone. Repeated injections of the peptide induced tolerance to analgesic response, catatonia and hypothermia. Cross tolerance to morphine was also observed.     

Immunoreactivity for β-endorphin in LH-RH neurons of the fetal human hypothalamus

Summary A peptide immunochemically related to -endorphin was detected in some LH-RH neurons of the fetal human hypothalamus by comparison of adjacent sections stained for -endorphin and for LH-RH. In the same section, by successive staining and after antibody elution, both peptides were again revealed in the same neuron. The significance of the presence of the -endorphin-like material in LH-RH neurons is discussed.     

The effect of β-endorphin on arginine-induced growth hormone and prolactin release

β-endorphin administration via constant infusion inhibited the release of growth hormone (GH) and augmented the release of prolactin (PRL) induced by arginine in normal female subjects. Although β-endorphin infusion also induced hyperglycemia, the increment in plasma glucose was insufficient to account for the observed suppression of arginine-initiated GH release. These studies demonstrate that β-endorphin influences, in opposed directions, the secretion of PRL and GH in women.     

Effect of β-endorphin on pulsatile luteinizing hormone release in conscious castrated rats

The effect of intraventricular administration of β-endorphin on pulsatile LH release in castrated conscious rats was studied. The administration of 1 μg of β-endorphin into the lateral ventricle inhibited pulsatile discharge of LH secretion. Intravenous administration of naloxone blocked the suppressive effect of β-endorphin on LH release. These results suggest a possible role of β-endorphin, in addition to Met⁵-enkephalin, in the control of LH release in male rats.